Donate
Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

Facebook Google LinkedIn Twitter

The law firm Hagens Berman has filed a complaint in Massachusetts* against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices.

The firm’s investigation shows that the publicly reported, list prices of Lantus, Levemir, Novolog and Humalog have increased by more than 160% in the last five years, while the prices offered to pharmacy benefit managers stayed constant or even decreased.

Background
In the drug pricing and distribution system, drug makers often offer lower prices to pharmacy benefit managers. However, in the case of Lantus, Levemir, Novolog and Humalog, Hagens Berman believe that the difference between the list price of insulin and the prices offered to pharmacy benefit managers is enormous.

Pharmacy benefit managers profit from these price discrepancies. Hagens Berman assert that the list prices of Lantus, Levemir, Novolog and Humalog have moved so far away from the real prices offered to pharmacy benefit managers that they are fraudulent. Not only is that practice illegal, it is harming people living with diabetes in painful and cruel ways.

You can read the full complaint by following this link.

People with Diabetes Fight Back
T1International has connected people living with type 1 diabetes to the legal team at Hagens Berman. Patients have shared their often painful experiences, and more are speaking out for change.

An excerpt from the complaint notes that: ‘’Plaintiffs describe going into debt, taking out loans, moving back in with their parents, and quitting school to pay for their insulin. One plaintiff stated that she often turns off the lights and lowers the heat in her house, attempting to keep her electrical bill as low as possible so she can afford her insulin.

The stress of this financial burden is all consuming: many plaintiffs describe a constant state of anxiety brought on by their inability to afford the rising insulin prices.’’

Steve Berman, lead counsel on this case, also told T1International: “These patients – plaintiffs in this lawsuit - have suffered physically, financially, and emotionally. But what most people do not know is that the pharmaceutical companies that have demanded higher and higher payments from patients each year actually offer much lower prices to other actors within the healthcare system, actors that control which medications patients take.

What’s more, the insulin makers have raised their prices so significantly just so that they can offer these other actors deeper discounts. The discounts serve as a quid pro quo for agreements to funnel patient business towards those drug makers.

The aim of this lawsuit is to bring the insulin makers’ deceptive and unfair conduct to light and to force an end to such behavior. This lawsuit seeks to compensate people living with diabetes who have been deeply harmed by the drug companies’ price increases. We are glad to have support from T1International on this case.”

Pharma’s Response
What about Eli Lilly’s new discount program or Novo Nordisk’s commitment to only single-digit price increase? T1International recently shared thoughts in reaction to those announcements. The Hagens Berman complaint has similar things to say:

‘’Long overdue, these affordability measures still do not end or even address the insidious practice of competing for PBM business based on the spread between benchmark and net price. Nor do they make whole the patients who have spent thousands of dollars out of pocket on long acting insulins for the past few years. Therefore, these measures fail to address the structural issues that have given rise to the price hikes that have hurt under-insured and uninsured diabetes patients for years.’’

Hagans Berman insulin pricing graphic
Images created by Hagens Berman

What’s Next?
This process will be a long one, and it could take years before we see any outcomes. There will also be a lot of pushback from the pharmaceutical companies to get the lawsuit thrown out, but Hagens Berman tell us they are prepared to fight. T1International is prepared to fight with them.

We will continue to share updates as and when we receive them.

We are continuing to collect testimony from people who have experienced negative impacts from the high prices. You can contact Elizabeth@t1international.com if you would like to find out more.

*Note: This case has been re-filed in New Jersey. You can learn more and read the complaint here

Related posts:

T1International Statement on Novo Nordisk and Sanofi Price Hikes

T1International Statement on Novo Nordisk and Sanofi Price Hikes

Sanofi and Novo Nordisk are celebrating the New Year with fresh price hikes on their decades-old insulin products. “Sanofi increased the price of its three main insulin brands by between 4.4 %- 5.2 % last week, while Novo Nordisk increased the price of its insulin products by just under 5% on Tuesday,” the Financial Times article said. Once again, shareholder profits will be increased on the backs of people with diabetes. Read more

Sanofi's Lantus is Overpatented and Overpriced

Sanofi's Lantus is Overpatented and Overpriced

The diabetes community knows the sting of high drug prices. Over the years, the prices of essential insulin has increased at an alarming rate, requiring patients to jump through higher hoops and make more difficult decisions to keep up with costs. But how did we reach the point where so many people with diabetes cannot afford the medicines they need? Our new report on Lantus may provide some insight. Read more

My Journey to Eli Lilly HQ for Answers

My Journey to Eli Lilly HQ for Answers

I was very nervous before going to confront the top executives of Eli Lilly and Company. But I was determined to tell them Alec’s story. They needed to hear from me what their insulin prices did to Alec, and are still doing to others. Read more

Taking a Stand at Eli Lilly Headquarters

Taking a Stand at Eli Lilly Headquarters

I joined dozens of people impacted by the rising cost of insulin in the USA in protest of those prices in front of Eli Lilly headquarters in Indianapolis, Indiana. Some had traveled many hours to join the protest, but one thing was made clear, we wanted to ensure that Eli Lilly heard our voices. We were passionate in our outcry for change and jointly understood that not saying anything is simply not an option.
Read more

Uninsured with diabetes in the USA

Uninsured with diabetes in the USA

I have had times of desperation where I have used expired insulin, skipped some meals and diluted my insulin with water until I could afford to buy my next vial, but I am alive. I would like to suggest a few things to those who are possibly facing a future with no insurance... Read more

Diabetes Debt: 3 Stories

Diabetes Debt: 3 Stories

When I was diagnosed with type 1 diabetes 38 years ago (March of 1979), my insulin cost my parents $10 a vial. Now, my co-pay for my insulin is $40 for the brand my insurance company wants me to use, or $60 for the brand that works better for me. If I choose to use my local pharmacy, and get my supplies for 3 months at a time, I have to pay the full amount of $120 for each Rx. If I use the insurance company and get everything via the mail, I only save $20. Read more

Diabetes and the “American Dream”

Diabetes and the “American Dream”

I was diagnosed with type 1 diabetes when I was 12, after my mom noticed I had lost an extreme amount of weight after three days at summer camp. She had my uncle, a type 2 diabetic test my blood sugar, like he had many times before because of my fascination with medical equipment. Except this time, something was wrong. Read more

America is Number 1 - in Diabetes Costs

America is Number 1 - in Diabetes Costs

Everyone likes being #1, and Americans are no exception. Few Americans will be celebrating that they have the world’s highest out of pocket costs for insulin and other life-saving diabetes supplies. Read more

Access to Health Care in the USA

Access to Health Care in the USA

In the US we are very lucky to have access to some of the best health care methods and technology in the world. I never have to worry about where my next pen of insulin will come from and I get to try out the latest tech and choose what works best for me, for the most part... Read more